. The ~85 subunit is composed of a Bcr homology domain, an Src homology3(SH3) domain, two proline-rich regions, and two SH2 domains (Escobedo et al., 1991; Skolnik et al., 1991; Otsu et al., 1991; Kapeller et al., 1994 (Ruderman et al., 1990; Backer et al., 1992b) . Nonetheless, the insulin receptor is able to activate other SH2containing proteins through the phosphorylation of adaptor proteins, including the insulin receptor substrates 1 and 2 (IRS-1 and IRS-2). Phosphorylated IRS-l is able to interact with PI 3-kinase, Grb-2, Syp, and Nck (White and Kahn, 1994) .
Several studies suggest that the PI 3-kinase lipid products, Ptdlns (3,4)P, and Ptdlns (3,4,5)P3, are important regulators of ceil proliferation (Cantley et al., 1991) . They are undetectable in quiescent cells and appear within seconds after growth factor stimulation (Auger et al., 1989) . Ptdlns (3)P levels, on the other hand, do not significantly change with cell stimulation. Furthermore, Ptdlns (3,4)P2 and Ptdlns (3, 4, 5) P3 are elevated in cells transformed by v-abl, v-sfc, and polyoma middle T, and decreased levels of these lipids correlate with impaired cell transformation by mutated forms of these oncogenes (Fukui et al., 1991; Varticovski et al., 1991; Cantley et al., 1991; Ling et al., 1992 et al., 1992b; Fantl et al., 1992; Valius and Kazlauskas, 1993; Jhun et al., 1994) . These approaches prevent activation of PI 3-kinase, but they provide little information about the direct targets of the lipid products.
With the identification of the drugs wortmannin (Yano et al., 1993; Okada et al., 1994) and Ly294002 (Vlahos et al., 1994) as potent PI 3-kinase inhibitors, it is possible to complement these experiments by directly and acutely inhibiting the activity of PI 3-kinase in intact cells. While investigating the effect of these inhibitors, we made the surprising observation that inhibition of insulininduced Ptdlns (3,4)P2 and Ptdlns (3,4,5)P3 formation correlates with increased association of PI 3-kinase protein with tyrosine-phosphorylated proteins. Investigation of this phenomenon led to the observation that Ptdlns (3,4,5)P3 directly binds to the SH2 domains of PI 3-kinase in competition with phosphoproteins.
We also show that other SH2 domains can bind Ptdlns (3,4,5)P3, raising the possibility that some physiological responses of PI 3-kinase are mediated by SHP-containing proteins.
Results
PI 3-Kinase Inhibition by Wortmannin and Ly294002 Stabilizes the Association of PI 3-Kinase with Tyrosine-Phosphorylated Proteins To test whether PI 3-kinase activation is important for insulin-induced association of PI 3-kinase with pTyr-containing proteins, we incubated CHO cells transfected with human insulin receptor (HIR cells) with the PI 3-kinase inhibitors Ly294002 or wortmannin for 15 min prior to insulin stimulation. In agreement with previous studies (Ruderman et al., 1990) insulin caused an increase in the amount of the 85 kDa subunit of PI 3-kinase that can be precipitated with anti-pTyr antibody in the absence of PI 3-kinase inhibitors (Figure 1 a) . Surprisingly, we observed afurther increase in the amount of ~85 present in anti-pTyr immunoprecipitates from insulin-stimulated cells that had been treated with either Ly294002 (500/o-80% increase) or wortmannin (1500/o-250% increase). The greater effect of wortmannin compared with Ly294002 is consistent with wortmannin being more effective than Ly294002 in blocking the insulin-dependent stimulation of Ptdlns (3,4,5)P3 production at the concentrations used (see below). While wortmannin inhibition of PI 3-kinase is irreversible, Ly294002 binding to PI 3-kinase is reversible and can be washed away during the immunoprecipitation procedures. Therefore, the amount of PI 3-kinase activity present in the antipTyr immunoprecipitates from Ly294002-treated cells reflects the amount of ~85 present (Figures 1 a and 1 c, lane  3) . On the other hand, the anti-pTyr immunoprecipitates from the wortmannin-treated cells show very little PI 3-kinase activity, despite the fact that they contain more ~85 protein (Figures la and lc, lane 4) .
The effects of Ly294002 and wortmannin on the association of PI 3-kinase with tyrosine-phosphorylated proteins were also investigated by immunoprecipitating with an anti-p85 antibody. This antibody has been shown to immunoprecipitate tyrosine-phosphorylated IRS-l (185 kDa) and, to a lesser extent, tyrosine-phosphorylated insulin receptor (95 kDa) in response to insulin (Backer et al., 1992a; Kelly and Ruderman, 1993 shown) detectable by anti-pTyr antibodies. Ly294002 and wortmannin did not significantly affect the total amount of p85 precipitated or the amount of tyrosine phosphorylation in total cell lysates and anti-pTyr immunoprecipitates (Figures le, If, and 1 b) . In agreement with previous results, very little pTyr was detected at the position of ~85 (data not shown). These results all indicate that inhibition of PI 3-kinase increases its association with tyrosine-phosphorylated proteins.
To understand better the effect of these PI 3-kinase inhibitors, we performed a time course of insulin stimulation in cells pretreated with dimethyl sulfoxide (DMSO), Ly294002, or wortmannin. Increased ~85 association with tyrosine-phosphorylated proteins in cells pretreated with Ly294002 (data not shown) and wortmannin ( Figure 2a ) was observed as early as 1 min after insulin stimulation. Acorrelation between PI 3-kinase inhibition and increased ~85 association with tyrosine-phosphorylated proteins was observed when cells were treated with different doses of wortmannin (Figure 2b ). The effect of wortmannin was observed at concentrations as low as 1 nM. Lipid analysis revealed that insulin-stimulated in vivo production of Ptdlns (3,4)P2 (Figure 2c ) and Ptdlns (3,4,5)P3 (Figure 2d ) was almost totally abolished by wortmannin treatment and only partially blocked by Ly294002 at the concentrations used in the experiments presented in Figures 1 and 2a . Thus, decreasing the amount of Ptdlns (3,4)P~ and Ptdlns (3,4,5)P3 correlates with an increase in the association of p85 with tyrosine-phosphorylated proteins. with anti-pTyr antibody, blotted for ~85, and quantified as described.
The standard errors (of three experiments)forthe 1 min insulin treatmentwere f 13%(control)and f 10% (wortmannin).
The data presented are representative of three experiments. (b) Serum-starved HIR cells were treated with different concentrations of wortmannin prior to insulin stimulation (100 nM). After 5 min, cells were lysed in NP-40 buffer, and the lysates were precipitated with anti-pTyr antibody. The precipitates ware assayed for PI 3-kinase activity (closed circles) and blotted for p85 protein (open circles) as in Figure  1 . PI 3-kinase-specific activity was calculated by dividing the relative activity by the relative amount of p85 protein. Error bars indicate the range from two experiments. (C and d) Serum-starved HIR ceils were labeled with =P inorganic phosphate for 4 hr, treated with DMSO (circles), 10 NM Ly294002 (squares), or 100 nM wortmannin (triangles), and then stimulated with insulin (time zero). Cells were lysed at the indicated time, and lipids were extracted, deacylated, and analyzed by high pressure liquid chromatography (HPLC) as described. The peaks corresponding to Ptdlns (3,4)P~ (c) and Ptdlns (3,4,5)P3 (d) were quantified and normalized to the total amount of 32P label in Ptdlns (4) Figure  3b ). Cells overexpressing full-length ~85, on the other hand, had increased levels of basal and insulin-stimulated anti-pTyr-associated p85 ( Figure  3b ), even though the levels of tyrosine-phosphorylated insulin receptor ( Figure  3c ) and IRS- mixture to provide an indication of the selectivity of each SH2 domain for individual phosphoinositides(Figure5). All three SH2 domains preferentially bound Ptdlns (3,4,5)P3. Full-length p85 was less selective for Ptdlns (3,4,5)P3, probably because of the additional site in the interSH2 of ~8.5 that binds Ptdlns (4)P and Ptdlns (4,5)P2 (End et al., 1993) . Of all the SH2 domains investigated, the Abl SH2 domain had the lowest affinity (Figure 4 ) and the least selectivity (1.8-fold selection for Ptdlns [3,4,5]P3 over other phosphoinositides; data not shown). No detectable Ptdlns (3,4,5)P3 was found associated with either GST alone or the GST-p85 SH3 in these experiments (data not shown). (3,4,5)P~, as well as with pTyr-containing proteins, for Src SH2 binding. A phosphopeptide with lower affinity for the Src SH2 domain (pYMPM; Songyang et al., 1993) competed at higher concentrations, while an unphosphorylated peptide containing the sequence YEEI did not significantly affect the lipid-SH2 interaction at concentrations up to 100 pM. Consistent with previous observations that a pYMPM-containing peptide binds specifically to the SH2 domains of p85 (Fantl et al., 1992; Songyang et al., 1993) , this peptide competed 50% of the phenyl phosphate-sensitive lipid binding to the ~85 amino-terminal SH2 at 10 PM, while at this concentration no competition was observed using the pYEEl peptide (data not shown). Thus, phosphopeptide competition for lipid binding occurs at the wellcharacterized phosphopeptide-binding sites. Binding of pTyr-containing peptides to SH2 domains is known to involve the arginine residue present in the FLVR sequence that is conserved among these domains. To determine whether lipid binding to SH2 domains also involves this arginine residue, GST-Src SH2 domain mutants were tested for their ability to bind the 3ZP-labeled PI 3-kinase lipid products. Substitution of the Arg-178 with lysine or glutamine did not decrease the ability of this SH2 domain to bind Ptdlns (3,4,5)P3 ( Figure 6~ ). However, consistent with the requirement of Arg-178 for pTyr binding, the ability of phenyl phosphate to compete for the lipid interaction was almost completely abolished by the Arg178+Lys mutation and was totally eliminated by the Arg-178*Gln mutation. As expected, the Arg-178+Lys mutant (in which the positive charge of the residue is maintained) was impaired in its capacity to bind tyrosine-phosphorylated proteins, and the Arg-178+Gln mutant (in which the positive charge is eliminated) was completely defective in pTyr-binding function (Figure 6d ). These results indicate that, while pTyr binding and Ptdlns (3,4,5)P3 binding are competitive, they do not utilize all the same positively charged residues of the pTyr-binding pocket. These re- asdescribed. Lysatesfrom insulin-stimulated HIR cells were added so that the final concentration of NP-40 was 0.5%. After 10 min, the beads were washed and the proteins associated were analyzed by anti-pTyr blotting. The scanned image of the insulin receptor band was quantified as described.
The results are expressed as a percentage of the total amount of insulin receptor associated with SH2 beads in the absence of lipids. Error bars represent the range from duplicate samples. suits also confirm that the phenyl phosphate competition for lipid binding occurs via the pTyr pocket.
Ptdlns (3,4,5)P3 Blocks In Vitro Binding of ~85 Carboxy-Terminal SH2 to Phosphorylated Insulin Receptor We also investigated whether Ptdlns (3,4,5)P3 and Ptdlns (4,5)P~ could interfere with the ability of SH2 domains to bind pTyr-containing proteins from a cell lysate. Figure 7 shows that synthetic dipalmitoyl Ptdlns (3,4,5)P3 (presented as NP-40-mixed micelles) blocks the binding of GST-~85 carboxy-terminal SH2 to the insulin receptor with a 50% maximal effect at approximately 5 PM (Ptdlns [3, 4, 5] P~ also inhibited ~85 carboxy-terminal SH2 binding to IRS-1 by 50% at 5 PM; data not shown). In agreement with the results in Figure 5 , Ptdlns (4,5)P2 micelles were less effective at blocking binding. Similar results were obtained when Ptdlns (3,4,5)P3 was presented in phosphatidylserine vesicles (data not shown). We also investigated the ability of inositol polyphosphates to block the Src SH2 domain binding to insulin receptor and found that inositol (1,3,4,5)P,, the head group of Ptdlns (3,4,5)P3, had a much lower affinity than Ptdlns (3,4,5)P3: inositol (1 ,3,4,5)P4 inhibited 29% of the insulin receptor binding at 1 mM concentration, while Ptdlns (3,4,5)P3 inhibited 90% at 80 KM. Nevertheless, it did bind better than inositol (1 ,4,5)P3, the head group of Ptdlns (4,5)P2, which inhibited only 14% of the insulin receptor binding at 1 mM concentration (data not shown). These results indicate that the diacylglycerol component of the lipid provides additional affinity.
Discussion
The data presented in this paper demonstrate a novel protein-lipid interaction between SH2 domains and a phosphoinositide product of PI 3-kinase, Ptdlns (3,4,5)P3. The ~85 amino-terminal and carboxy-terminal SH2 domains and the Src SH2 domain had specificity for binding Ptdlns (3,4,5)P3 over other phosphoinositides.
The Lck and Abl SH2 domains also had significant, although weaker, binding to Ptdlns (3,4,5)P3. The ability of phenyl phosphate and tyrosine-phosphorylated peptides to block the Ptdlns (3,4,5)P3-SH2 interaction indicates that lipid binding and phosphopeptide binding are mutually exclusive. The arginine at position 178 of the Src SH2 domain is required for pTyr binding, but not for Ptdlns (3,4,5)P3 binding, indicating that lipid and phosphoprotein interactions with SH2 domains are not coordinated by the same residues inside the pocket.
Evidence that PI 3-kinase lipid products compete with pTyr-containing proteins for binding to the p85 subunit of PI 3-kinase in vivo is provided by experiments with PI 3-kinase inhibitors and by overexpression of dominant positive PI 3-kinase. Blocking the production of Ptdlns (3,4,5)P3 with wortmannin or Ly294002 enhances pTyr-~85 protein interactions, while expression of constitutively active PI 3-kinase reduces pTyr-p85 protein interactions.
These results suggest some interesting models for the involvement of PI 3-kinase in signal transduction. It is likely that local concentrations of Ptdlns (3,4,5)P3 will be enough to bind to the SH2 domain of ~85 since the lipid is synthesized locally by the catalytic subunit of this protein. This could be an effective mechanism of dissociating PI 3kinase from tyrosine-phosphorylated proteins once the lipid product has reached an optimal level, providing a negative feedback control mechanism. However, it is also possible that the Ptdlns (3,4,5)P3 recruits a subgroup of SH2-containing proteins to specific compartments of the cell. For example, binding of Grb-2 to Ptdlns (3,4,5)P3 could be an alternative mechanism to binding of Grb-2 to receptors for recruiting the Grb9-SOS complex to the plasma membrane. Ptdlns (3,4,5)P3 binding to the SH2 domain of p~60~-~~ could also be important for the localization or activation of this enzyme (or for both). Experiments to test these ideas are in progress.
To date, PI 3-kinase has been implicated in a plethora of cellular responses, including mitogenesis (Whitman et al., 1985; Kaplan et al., 1987; Coughlin et al., 1989; Cantley et al., 1991) , chemotaxis (Kundra et al., 1994; WennStrom et al., 1994) , membrane ruffling (Wennstrom et al., 1994) , activation of p7OS6 kinase (Chung et al., 1994) insulin-dependent Glut4 recruitment (Cheatham et al., 1994; Clarke et al., 1994) , glycogen synthesis (Cross et al., 1994; Welsh et al., 1994) , activation of integrins in platelets (Kovacsovics et al., 1995) , histamine release (Yano et al., 1993) , receptor down-regulation (Joly et al., 1994) , and blocking apoptosis (Yao and Cooper, 1995) . In addition, the yeast homolog of PI 3-kinase, Vps34p (which produces Ptdlns [3]P but not Ptdlns [3,4]P2 or Ptdlns [3,4,5]P3), is required for trafficking of proteins from the Golgi to the vacuole (Herman and Emr, 1990; Hiles et al., 1992) . It seems unlikely that a single target for the D3 phosphoinositides mediates these diverse responses. Thus, it is an attractive idea that various SH2 domains bind to specific D3 phosphoinositides to mediate distinct responses.
The fact that Ptdlns (3,4)Pn and Ptdlns (3,4,5)P3 are normally undetectable in quiescent cells and appear within seconds to minutes of stimulation with various growth factors or hormones is consistent with these molecules acting as second messengers (Auger et al., 1989) . In addition to the evidence presented here that SH2 domains bind to Ptdlns (3,4,5)P3, we have previously shown that both Ptdlns (3,4)P2 and Ptdlns (3,4,5)P3 activate protein kinase C types E, n, and 6 (Toker et al., 1994) . Activation of native protein kinase C-c (Nakanishi et al., 1993), but not recombinant protein kinase C-c (Toker et al., 1994) has also been reported. Interestingly, Ptdlns (3,4)P2 is more effective than Ptdlns (3,4,5)P3 in activating the Ca2+-independent protein kinase C isoforms (Tokeret al., 1994) , while Ptdlns (3,4,5)P3 is more effective than Ptdlns (3,4)P2 in binding to the Src and ~85 SH2 domains ( Figure 5) . Recently, Ptdlns (3)P was implicated in the activation of the Akt Ser/Thr protein kinase via a Plekstrin homology domain (Franke et al., 1995) . These results raise the possibility that the different lipid products of PI 3-kinase preferentially activate different targets in the cell and begin to provide a framework for understanding the diverse cellular responses in which PI 3-kinase has been implicated.
Experimental Procedures
Cell Culture CHO cells transfected with wild-type HIR (White et al., 1988) were cultured in RPM1 medium containing 10% FCS and 0.4 mglml 6418 until they reached 80% confluence.
Cells were serum starved in RPM1 containing 0.5% bovine serum albumin (BSA) for 48 hr. For the PI 3kinase inhibitor experiments, cells were treated with DMSO carrier, 10 pM Ly294002 (Lilly) in DMSO, or 100 nM wortmannin (Sigma) in DMSO for 15 min prior to insulin stimulation.
Transient
Transfection HIR cells were cultured in 100 mm dishes until they reached 70% confluence. We used 8 ug of plasmid DNA(pRC [lnvitrogen] containing the cytomegalovirus
[CMV] promoter, CMV-~85, or CMV-iSH2) and 48 ul of lipofectamine reagent (GIBCO BRL) to transfect each plate in the absence of serum. After 18 hr, the medium was replaced by RPMI-O.5% BSA. Approximately 45 hr after the beginning of the transfection, the cells were or were not stimulated with 100 nM insulin and lysed as described below. The CMV-iSH2 plasmid is a construct containing the Myc tag sequence fused to the carboxy-terminal sequence of the iSH2 region (amino acids 428-678) of the human p85 cDNA, cloned into a vector containing the CMV promoter. The CMVp85 plasmid was constructed by fusion of the Myc tag sequence to the amino-terminal sequence of the bovine p85 cDNA and cloning into a vector containing the CMV promoter. lmmunoprecipitation and lmmunoblot Cells were lysed in 1 ml of NP-40 lysis buffer (137 mM NaCI, 20 mM Tris-HCI [pH 7.51, 1 mM MgC&, 1 mM CaC12, 10% glycerol, 1% NP-40) containing protease inhibitors (I ttglml leupeptin, 1 uglml aprotinin, 1 uglml pepstatin, and 1 mM PMSF) and phosphatase inhibitor (1 mM sodium vanadate).
Cells were scraped after rocking for 15 min at 4OC, and the lysates were cleared by centrifugation at 15,000 rpm for 10 min. Variations in the total protein concentration of different cell lysates (measured using the Bio-Rad protein assay reagent) were less than 7%.
Antibody and protein A-Sepharose were added to lysates, and the mixture was incubated at 4°C for 3 hr. lmmunoprecipitates were washed three times with PBS-l% NP-40, twice with 0.5 M LiCI, 0.1 M Tris-HCI (pH 7.5), and twice with IO mM Tris-HCI (pH 7.5) 100 mM NaCI, 1 mM EDTA and were assayed for PI bkinase activity, using Ptdlns (4,5)P2 as a substrate as previously described (Serunian et al., 1991) or were denatured in Laemmli's buffer for 10 min at 100°C. Proteins present in the immunoprecipitates were separated by 7.5% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane. After blocking with TBS (20 mM Tris-HCI ]pH 8.01, 137 mM NaCI) containing 5% lowfat milk, the membranes were incubated with primary antibody for 1 hr in TBS-0.05% Tween 20 for 45 min with secondary antibody conjugated with HRP and developed using the chemiluminescence detection system (DuPont). The anti-p85 antibody was obtained from UBI, and the anti-pTyr antibody (4GlO) was a gift from Dr. T. Roberts. The scanned images of autoradiograms were quantified using the NIH image program. For the kinetics experiments ( Figure Za) , the amount of ~85 was calculated based on a p85 standard curve obtained from immunoblots of p85 containing serial dilutions of the protein.
In Vivo Labeling of Lipids and HPLC Analyses HIR cells were labeled with 0.5 mCi/ml of inorganic [-PIphosphate for 4 hr. After being treated with inhibitors as described above, cells were stimulated with insulin for 2.5, 5, IO, or 20 min at 37'C. One 100 mm plate was used for each timepoint. Cells were harvested with 800 ~1 of methanol, 1 M HCI (1:l). Lipids were extracted with 400 ~1 of chloroform, deacylated, and analyzed by high pressure liquid chromatography (HPLC) on a SAX column, as described previously (Serunian et al., 1991) . The peaks corresponding to the deacylated products of Ptdlns (3,4)P~ and Ptdlns (3,4,5)P3 were identified with the use of 3H standards, and the radioactivity present in each peak was quantified with the use of an on-line radiomatic detector (Packard) and normalized to the total amount of =P label in Ptdlns (4)P plus Ptdlns (4,5)P~. For the experiment shown in Figures 2c and 2d were prepared by incubating the precursor of these lipids with purified PI 3-kinase in the presence of excess phosphatidylserine'as previously described (Carpenter et al., 1990) . After 2 hr at room temperature, the reaction was stopped with IO mM EDTA, and lipids were isolated by chloroform:methanol extraction as described previously (Serunian et al., 1991) . For the lipid selection experiments, a 200 pM solution of presonicated crude brain phosphoinositides was incubated with purified PI 3-kinase, Ptdlns 4-kinase, and Ptdlns (4)P 5-kinase in the presence of 15 mM HEPES (pH 7.0) 200 pM [32P]ATP (1 .I t0/mmol), and 5 mM MgC&. The lipids were extracted with chloroform:methanol and dried. Dry lipids were resuspended in 10 mM HEPES (pH 7.0), 1 mM EDTA, sonicated, and added to 40 nl of Sepharose beads containing approximately 12 ng of the indicated GSTfusion protein in the absence or presenceof 20 mM phenyl phosphate in asolution containing 0.02% NP40-HNE buffer. A titration experiment has shown that at 0.02% NP-40 lipid binding is optimal. Incubation was carried out for 1.5 hr at room temperature, after which the beads were quickly washed twice with 1 ml of 0.5% NP-40-HNE (2-3 min total). Lipids that remained associated with the beads were extracted with chloroform:methanol (1 :I) and resolved by thin-layer chromatography (TLC) using l-propanol:2 M acetic acid (65:35 v/v) . A sample of the original lipid mixture was also run on the TLC. The peptide competition experiments were done in the presence of the peptides RENEpYMPMAPQlH (pYMPM), EPQpYEElPlYL (pYEEI), or AEEEElYEEfEAKKKK (YEEI), as described above (pY indicates pTyr). The results were quantified using a phosphorimager (Bio-Rad). For the lipid selectivity experiments ( Figure 5 ) the bound lipids were deacylated and analyzed by HPLC as described previously (Serunian et al., 1991) . The radioactivity in each lipid was then divided by the radioactivity in the same lipid in the starting mixture to determine the fraction of each lipid bound to a given SH2 domain. To compare the relative selectivities of the various SH2 domains for Ptdlns (3,4,5)P,, the data were normalized such that if all the lipids bound equally well, each would have a selectivity of I. Total radioactivity bound in the experiments presented is as follows: ~85, 12,473 dpm; ~8.5 carboxy-terminal SH2,9,603 dpm; ~85 amino-terminal SH2,5,607 dpm; Abl SH2, 2,724 dpm; Src SH2, 7,437 dpm; GST, 1,219 dpm; ~85 SH3, 1,440 dpm; total (before SH2 selection), 11,439O dpm. The radioactivity from the GST and ~85 SH3 experiments did not appear above background in any of the phosphoinositide elution positions. The proportions of [32P]phosphoinositides in the starting mixture were as follows: Ptdlns (3)P, 39%; Ptdlns (4)P, 14.6%; Ptdlns (3,4)P2, 9.5%; Ptdlns (4,5)Pz, 25.5%; Ptdlns (3,4,5)P3, 11.3%.
